Acasti Pharma Inc. (ACST) |
|
0.4202 -0.015 (-3.4%)
|
03-24 10:47 |
|
Open: |
0.44 |
Pre. Close: |
0.435 |
|
High:
|
0.44 |
Low:
|
0.42 |
|
Volume:
|
16,076 |
Market Cap:
|
19(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 10:14:35 AM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.64  One year: 0.75 |
| Support: |
Support1: 0.4 Support2: 0.33 |
| Resistance: |
Resistance1: 0.55 Resistance2: 0.64 |
| Pivot: |
0.45 |
| Moving Average: |
MA(5): 0.44 MA(20): 0.47
MA(100): 0.54 MA(250): 0.74 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 36.1 %D(3): 38.9 |
| RSI: |
RSI(14): 31.5 |
| 52-week: |
High: 1.35 Low: 0.34 |
| Average Vol(K): |
3-Month: 161 (K) 10-Days: 49 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACST ] has closed above bottom band by 22.5%. Bollinger Bands are 54.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.48 - 0.48 |
0.48 - 0.49 |
|
Low:
|
0.41 - 0.42 |
0.42 - 0.42 |
|
Close:
|
0.43 - 0.44 |
0.44 - 0.44 |
|
Company Description |
|
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada. |
Headline News |
Mon, 13 Mar 2023
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange - Yahoo Finance
Wed, 08 Mar 2023
Acasti Pharma to Participate in Oppenheimer 33rd Annual ... - Benzinga
Tue, 28 Feb 2023
Acasti Pharma Recognizes Rare Disease Day - PR Newswire
Wed, 15 Feb 2023
Acasti Pharma Inc. (NASDAQ:ACST) Q3 2023 Earnings Call Transcript - Yahoo Finance
Thu, 29 Dec 2022
Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript - Yahoo Finance
Wed, 28 Dec 2022
Acasti Announces Preliminary Topline Results Met All Outcome ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
45 (M) |
| Shares Float |
36 (M) |
|
% Held by Insiders
|
20.2 (%) |
|
% Held by Institutions
|
0.1 (%) |
|
Shares Short
|
304 (K) |
|
Shares Short P.Month
|
163 (K) |
Stock Financials |
|
EPS
|
-0.34 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.74 |
|
EPS Est Next Year
|
-0.77 |
|
Book Value (p.s.)
|
2.17 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-8.3 |
|
Return on Equity (ttm)
|
-16.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.34 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-16 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
-1.32 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.2 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.24 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
